Clinical Trial Detail

NCT ID NCT01872260
Title Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

progesterone-receptor positive breast cancer

estrogen-receptor positive breast cancer

Therapies

Alpelisib + Letrozole

Alpelisib + Letrozole + Ribociclib

Letrozole + Ribociclib

Age Groups: senior adult

Additional content available in CKB BOOST